Peripheral Neuropathy News and Research

RSS

Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.

Researchers identify genetic factor linked to development of diabetic peripheral neuropathy

Researchers from Joslin Diabetes Center, using a genome-wide association study, have identified a genetic factor linked to the development of diabetic peripheral neuropathy.

12 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

University of Virginia chemist identifies potential addiction-free pain reliever

An estimated 1.7 million Americans suffer from substance abuse disorders related to opioid use for pain relief, according to the National Institute on Drug Abuse.

17 May 2019

Processed aconite root could relieve neuropathic pain in murine peripheral neuropathy

The root of Aconitum carmichaeli, is a crude drug used in traditional Chinese or Japanese kampo medicine to treat pain associated with coldness.

11 Apr 2019

IUPUI researcher receives $2.85 million grant to find ways to improve bone strength

A $2.85 million National Institute of Arthritis and Musculoskeletal and Skin Diseases-funded study at IUPUI will advance understanding of how bone cells sense and respond to mechanical force, one of the cues the skeleton relies on to regulate its strength.

21 Jan 2019

Scientists develop new gene therapy that prevents axon destruction in mice

Nerve axons serve as the wiring of the nervous system, sending electrical signals that control movement and sense of touch.

18 Jan 2019

Statins associated with low risk of side effects

The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients.

10 Dec 2018

New first-line treatment for peripheral T-cell lymphoma approved by FDA

The U.S. Food and Drug Administration today expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

16 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Study finds differences in side-effects experienced by male and female OG cancer patients

Men and women may need to be treated differently - at least when it comes to some types of cancer. In an analysis to be presented at the ESMO 2018 Congress in Munich, data was pooled from four UK randomized controlled clinical trials of first line chemotherapy in oesophagogastric cancer, finding significant differences in a number of important side-effects experienced by male and female patients.

19 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury.

25 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Research provides better understanding of zinc deficiency-induced peripheral neuropathy

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is honoring Favio C. Bumanlag, BA, with the 2018 Technologist Member Recognition Award for his abstract, Clinical, Laboratory, and Electrodiagnostic Features of Zinc Deficiency-induced Peripheral Neuropathy.

3 Sep 2018

Scientists turn to C. elegans for new model of peripheral neuropathy

Studying transthyretin amyloidoses-;a group of progressive nerve and cardiac degenerative diseases caused by the buildup of misfolded transthyretin proteins in the body-;has long been hampered by the lack of animal models of the disease.

9 Aug 2018

Regenacy Pharmaceuticals partners with CMTA to advance ricolinostat for treating hereditary neuropathy

Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association, a registered non-profit organization serving the hereditary neuropathy patient community, to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models.

2 Aug 2018

Novel therapeutic approach alleviates ALS-related muscular atrophy in mouse models

Supplementing a single protein found in the spinal cord could help prevent symptoms of Lou Gehrig's disease, according to a new study out of Case Western Reserve University School of Medicine.

12 Jul 2018

FDA requires safety labeling changes for fluoroquinolones to strengthen warnings on adverse reactions

The U.S. Food and Drug Administration today is requiring safety labeling changes for a class of antibiotics called fluoroquinolones to strengthen the warnings about the risks of mental health side effects and serious blood sugar disturbances, and make these warnings more consistent across the labeling for all fluoroquinolones taken by mouth or given by injection.

11 Jul 2018

Whisk's innovative Culinary Coach selected as winner of Ascensia Diabetes Challenge

Today, at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that set out to find digital solutions to support type 2 diabetes management.

25 Jun 2018

Pediatric neuroblastoma patients have high risk of long-term psychological impairment

A new study reveals that pediatric neuroblastoma patients are at elevated risk for long-term psychological impairment. In addition, those who experience such impairment as they get older tend to require special education services and to not go on to college.

11 Jun 2018